How did FEMY's revenue and expenses trend in Q4 2024 compared to previous quarters?

Femasys Inc. (FEMY) experienced an increase in revenue and a rise in expenses in Q4 2024 compared to the previous quarter, Q3 2024.

1. **Revenue Trend**:
- FEMY's revenue for Q4 2024 was $581,576.
- In Q3 2024, the revenue was $271,140.
- This indicates a significant increase in revenue from Q3 to Q4, likely due to increased sales of their products, especially FemaSeed and FemVue.

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|FEMY|FEMY.O|Femasys|2023 Q4|-9.02178924540223|213111|186|
|FEMY|FEMY.O|Femasys|2024 Q1|-7.77049091106999|271140|186|
|FEMY|FEMY.O|Femasys|2024 Q2|-30.897246298133624|221484|186|

2. **Expense Trend**:
- Unfortunately, there are no available data on FEMY's expenses for Q4 2024.
- However, we do know that FEMY's net loss widened to $5.4 million in Q3 2024, compared to $4.0 million in Q3 2023, indicating a trend of increasing expenses.
- The increase in net loss suggests that while revenue increased, the company's expenses also rose, possibly due to factors such as increased marketing and distribution costs, research and development expenses, and operational costs associated with scaling up production and commercialization efforts.
3. **Comparison with Previous Quarters**:
- FEMY's revenue and expenses in Q4 2024 are not directly comparable to the previous year's Q4 due to the absence of Q4 2023 data. However, the trend of increasing revenue and expenses from Q3 to Q4 is consistent with the company's growth initiatives and the achievement of FDA clearance for their product FemaSeed.
- The company's strategic moves, such as securing capital to fund operations into the second half of 2025 after receiving FDA clearance for FemaSeed, suggest that expenses are likely to remain elevated as the company invests in commercialization and growth.

In conclusion, FEMY saw a notable surge in revenue in Q4 2024, which may have been accompanied by a corresponding increase in expenses, based on the trends observed in the net loss data from the previous quarter.